Messages For Your Health: A Cancer Screening Prevention Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02376023|
Recruitment Status : Unknown
Verified February 2017 by Javiera Martínez, Pontificia Universidad Catolica de Chile.
Recruitment status was: Recruiting
First Posted : March 3, 2015
Last Update Posted : February 9, 2017
|Condition or disease||Intervention/treatment||Phase|
|Cervical Cancer||Other: mHealth||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||400 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Development of Mobile Technologies for the Prevention of Cervical Cancer in Santiago, Chile: A Randomized Controlled Trial.|
|Actual Study Start Date :||February 22, 2016|
|Estimated Primary Completion Date :||May 2017|
|Estimated Study Completion Date :||December 2017|
Women in the mHealth group will receive text and voice messages, in addition to their habitual care from the health clinic they attend. The messages will remind them to schedule a PAP smear, and will be sent for 1 year following enrollment in the study.
Text and voice messages sent to study participants reminding them to schedule a PAP smear.
No Intervention: No mHealth
Women in the No mHealth group will not receive any text messages, and will only receive their habitual care from the health clinic they attend.
- Proportion of women who received a Pap smear within 6 months from the date when the study randomization began. [ Time Frame: 6 months after randomization of study ]The information will be collected from the cancer registration and monitoring database (CITOEXPERT/REVICAN), where Pap data of the population at the national level is registered. Investigators will also review medical records from participating patients at the two health centers. The data collection will take place 6 months after initial recruitment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02376023
|Contact: Javiera Martínez, MD, MPH||(56) email@example.com|
|CESFAM El Roble||Recruiting|
|Santiago, RM, Chile, 8820814|
|Contact: Francis Ciampi, Nurse 225435479 firstname.lastname@example.org|
|CESFAM Juan Pablo II||Recruiting|
|Santiago, RM, Chile, 8831695|
|Contact: Javiera Martinez-Gutierrez, MD, MPH 56224822410 email@example.com|
|Study Chair:||Carmen Huerta||Comisión Nacional de Investigación Científica y Tecnológica|